🇺🇸 FDA

Company profile · Sponsor

Argenx

ED90554 · EMA pharma EU
Pipeline
24
Drugs
0
Patents
0

Quick answer

Argenx (ED90554) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker ED90554
Exchange EMA
Company type pharma
Headquarters EU

Pipeline (24)

Search pipeline →

  1. ARGX-113

    Argenx

    Primary Immune Thrombocytopenia

    phase 3 small molecule active

    1 trial

  2. ARGX-113

    Argenx

    Primary immune thrombocytopenia

    phase 3 small molecule active

    1 trial

  3. ARGX-113, Vyvgart 20 mg/mL concentrate for solution for infusion, Vyvgart 1 000 mg solution for injection

    Argenx

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  4. Efgartigimod, Placebo for efgartigimod

    Argenx

    Thyroid Eye Disease (TED)

    phase 3 small molecule active

    1 trial

  5. HUMAN NORMAL IMMUNOGLOBULIN (IV), Placebo for empasiprubart- solution for IV infusion, Placebo for IVIg - solution for IV infusion, ARGX-117

    Argenx

    Chronic inflammatory demyelinating polyneuropathy (CIDP)

    phase 3 small molecule active

    1 trial

  6. PBO PH20 SC, ARGX-113

    Argenx

    Bullous Pemphigoid

    phase 3 small molecule active

    1 trial

  7. PREDNISONE, PREDNISONE, ARGX-113, PREDNISONE, PREDNISONE, PBO PH20 SC

    Argenx

    Bullous Pemphigoid (BP)

    phase 3 small molecule active

    1 trial

  8. Placebo efgartigimod IV concentrate for solution, ARGX-113, Vyvgart 20 mg/mL concentrate for solution for infusion

    Argenx

    Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  9. Placebo for efgartigimod, ARGX-113

    Argenx

    Chronic Idiopathic thrombocytopenic purpura

    phase 3 small molecule active

    1 trial

  10. Placebo for efgartigimod, ARGX-113, Vyvgart 20 mg/mL concentrate for solution for infusion

    Argenx

    Primary Immune thrombocytopenia (ITP)

    phase 3 small molecule active

    1 trial

  11. Placebo for empasiprubart- solution for IV infusion, ARGX-117

    Argenx

    Chronic inflammatory demyelinating polyneuropathy (CIDP)

    phase 3 small molecule active

    1 trial

  12. Placebo matching IMP., Vyvgart 1 000 mg solution for injection in pre-filled syringe

    Argenx

    Primary Sjögren’s Disease

    phase 3 small molecule active

    1 trial

  13. Placebo solution for IV infusion, ARGX-117, HUMAN NORMAL IMMUNOGLOBULIN (IV), Placebo solution for IV infusion, HUMAN NORMAL IMMUNOGLOBULIN (IV)

    Argenx

    Multifocal Motor Neuropathy

    phase 3 small molecule active

    1 trial

  14. Placebo to ARGX-113 solution for injection, ARGX-113

    Argenx

    Active Idiopathic Inflammatory Myopathy (IIM)

    phase 3 small molecule active

    1 trial

  15. Vyvgart 1 000 mg solution for injection

    Argenx

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  16. Vyvgart 1 000 mg solution for injection in pre-filled syringe, Placebo PH20 SC

    Argenx

    Ocular Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  17. Vyvgart 1 000 mg solution for injection in pre-filled syringe, Placebo for efgartigimod

    Argenx

    Thyroid Eye Disease (TED)

    phase 3 small molecule active

    1 trial

  18. Vyvgart 20 mg/mL concentrate for solution for infusion

    Argenx

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  19. Vyvgart 20 mg/mL concentrate for solution for infusion

    Argenx

    Generalized Myasthenia Gravis (gMG)

    phase 3 small molecule active

    1 trial

  20. A Phase 1b study to investigate safety and tolerability of ARGX-119 in adult participants with DOK7 Congenital Myasthenic Syndrome (CMS)

    Argenx

    congenital neuromuscular disorders

    phase 2 other active

    1 trial

  21. ARGX-117, ARGX-113

    Argenx

    AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG

    phase 2 small molecule active

    1 trial

  22. Efgartigimod, ARGX-113

    Argenx

    Chronic Inflammatory Demyelinating Polyneuropathy

    phase 2 small molecule active

    1 trial

  23. Placebo PH20 SC – prefilled syringe (placebo to Efgartigimod PH20 SC – prefilled syringe), Efgartigimod

    Argenx

    Antibody-Mediated Rejection

    phase 2 small molecule active

    1 trial

  24. Placebo to ARGX-117 IV concentrate solution for infusion, ARGX-117

    Argenx

    Myositis, Dermatomyositis

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is Argenx?

Argenx (ED90554) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Argenx sponsor?

We track 24 ClinicalTrials.gov-linked programs for Argenx, including ARGX-113 and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Argenx company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.